Trials / Completed
CompletedNCT05109078
ADME Study of [14C]- Rongliflozin in Healthy Male Subjects
Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]- Rongliflozin in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Study to Evaluate the Mass Balance and Biotransformation of Single Dose \[14C\]- Rongliflozin in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]- Rongliflozin | Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1 |
Timeline
- Start date
- 2021-12-09
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2021-11-05
- Last updated
- 2023-04-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05109078. Inclusion in this directory is not an endorsement.